top of page

Research Roundup: Oct 17, 2022

Best of cannabinoid science this week...

In a Florida survey of medical cannabis patients, 79% reported a reduction in their pain medication use Medical Cannabis Patients Report Improvements in Health Functioning and Reductions in Opiate Use

In humans, a pilot study showed that THC helped to extinguish fear conditioning induced by visual stimuli & electric shocks

Facilitated extinction of conditioned fear responses by delta 9-tetrahyrdrocannabidol in humans: a pilot study

Targeting the ECS for the pain of irritable bowel syndrome Targeting the endocannabinoid system for the treatment of abdominal pain in irritable bowel syndrome

A review found that across all trials they looked at for the nausea & vomiting of chemotherapy, cannabis worked better than conventional antiemetics

Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy

In the treatment of fibromyalgia, a review of 10 studies found that cannabis may be beneficial to patients & that no serious adverse events occurred Safety and Efficacy of Medicinal Cannabis in the Treatment of Fibromyalgia: A Systematic Review

2021: In a mouse model of colitis, THC prevented the disease via the immune cells & colon cells while CBD, at the doses tested, did not Cannabinoid Receptor Activation on Haematopoietic Cells and Enterocytes Protects against Colitis

In a rodent model of opioid use disorder, a negative allosteric modulator of the CB1 receptor (similar to CBD) blocked the rewarding effects of morphine & reduced consumption of oxycodone Negative allosteric modulation of CB1 cannabinoid receptor signaling suppresses opioid-mediated reward


bottom of page